My Watchlist
Subscribe and get alerts for the stocks and topics you follow
|
|
Genentech Inc. (DNA)
Add to Watchlist
|
|
Filed under: Wal-Mart (WMT), PepsiCo (PEP), Johnson and Johnson (JNJ), Colgate-Palmolive (CL), Genentech Inc (DNA)The Wall Street Journal argues that the stock market drop may have killed so many sectors that "defensive stocks" may have disappeared. In many market corrections, there are some compani...
|
|
|
I used to, and will one day return, to posting the best performing stocks of the week - but the wicked volatility and "student body left" trading of the past 4 months has made it a moot point. Everything must either be bought or sold, as stocks are either deemed "good" or "bad" that hour, day, or m...
|
|
|
bloggingstocks.com
-
Dec 02, 2008
about
PALM, DNA
Filed under: Palm Inc (PALM), Genentech Inc (DNA), OptionsMosaic (NYSE: MOS), a producer of crop nutrients, is recently down 81c to $24.59. MOS announced Q2 2009 results will be severely impacted by soft global demand for fertilizers. MOS December and January option implied volatility of 131 is abov...
|
|
|
oldprof.typepad.com
-
Nov 26, 2008
about
RMD, DNA
Jeff is traveling, so we are republishing his recent interview from the Kirk Report, one of our featured sources. The Kirk Report is an excellent investor resource, with many specific stock ideas for members. Charles Kirk also reads very widely and provides regular links to articles we might other...
|
|
|
Filed under: After the bell, Berkshire Hathaway (BRK.A), Market matters, Citigroup Inc. (C), Whole Foods Market (WFMI), Genentech Inc (DNA)Today's atrocious housing data was already a given, and the markets keyed off of additional strength from Friday on the introduction of the Obama Financial team...
|
|
|
bloggingstocks.com
-
Nov 24, 2008
about
DNA
Filed under: Major movement, Good news, Genentech Inc (DNA), Options, Technical AnalysisGenentech (NYSE: DNA - option chain) shares have moved higher today after the company and its partner Roche announced its breast-cancer drug Avastin improved the survival time for patients in a late-stage study....
|
|
|
investors.com
-
Nov 04, 2008
about
DNA
Genentech (DNA) gapped up 15% on July 21 when Swiss drug developer Roche Holding (RHHBY) made an $89 per share buyout offer for the 44% of the...
|
|
|
247wallst.com
-
Oct 14, 2008
about
DNA
After today's close, we are expecting the earnings report of of biotech giant Genentech, Inc. (NYSE: DNA). First Call has estimates targeted at $0.88 EPS on...
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
|
|
|
thestreet.com
-
Oct 13, 2008
about
DNA, GILD
How much do you know about investing in biotech companies? Go beyond the hype with TheStreet.com
|
|
|
Consolidation in the Healthcare Industry - Analysis and Discussion with Sachin Shah of ICAP
|
|
|
bloggingstocks.com
-
Oct 08, 2008
about
DNA, IBM
Filed under: International Business Machines (IBM), Genentech Inc (DNA), OptionsGenentech (NYSE: DNA) closed at $78.19 Tuesday. Roche announced on July 21 the offer to buy the balance of 44% of DNA it does not own for $89 cash. DNA November option implied volatility of 60 is above its 26-week averag...
|
|
|
fool.com
-
Oct 03, 2008
about
AMGN, DNA
The pharmaceutical fights off rival Roche.
|
|
|
minyanville.com
-
Aug 28, 2008
about
AMGN, DNA, OIH and 9 moreSMH, RKH, GILD, HD, RTH, PPH, BBH, WMT, LOW
When it comes to ETFs the Retail HLDRS (RTH) can be a poor proxy for retail in general (too concentrated on Wal-Mart (WMT) Home Depot (HD) and Lowe’s (LOW). On the subject of poorly-weighted ETF's RTH is certainly up there but the biotech holders (BBH) takes the cake in my opinion. One stock Genente...
|
|
|
adamsoptions.blogspot.com
-
Aug 28, 2008
about
DNA, HHH
Some discussion yesterday on Minyanville regarding the RTH and the poor proxy it can be for retail in general (too concentrated on WMT, HD and LOW).On the subject of poorly-weighted ETF's, RTH is certainly up there, but BBH, the biotech holders, takes the cake imho. One stock, Genentech (DNA) , acc...
|
|
|
fundmymutualfund.com
-
Aug 15, 2008
about
AMLN, DNA, VRTX and 16 moreGLD, FBT, OSIP, GENZ, CEPH, XBI, PDLI, AMGN, IMCL, AFFX, GILD, BIIB, BBH, CELG, ILMN, IF
One area you can see I've been transitioning into is healthcare. I still don't buy the "technology is a safe haven" thesis but I have to respect that's where money flow is going. Healthcare I can feel a bit more comfortable with because it's a traditional safe haven in times of recession. Not tha...
|
|
|
clusterstock.com
-
Aug 15, 2008
about
DNA
Citigroup analyst Yaron Werber downgrades Genentech (DNA), arguing that Roche will not increase its bid as much as the market thinks.
Werber reasons that Genetech has lots of upside given the success of its Adjuvant cancer treatment. This being the case, Werber thinks that Roche will rush to get the...
|
|
|
PREMIUM FOR DNA MAY NOT BE WORTH IT
Here’s some right-thinking sell-side research: expect Genentech (DNA) to field a much sweeter takeover offer from its suitor Roche. But don’t go buying Genentech shares at these levels - a significant discount to the presumed takeover price - because it’s not wort...
|
|
|
notablecalls.blogspot.com
-
Jul 21, 2008
about
BIIB, DNA, MS
Merrill Lynch upgrades Biogen-Idec (NASDAQ:BIIB) to Buy from Underperform based on their assessment of the company’s earnings growth potential, an improved outlook in the multiple sclerosis (MS) market, and a diversified mid to late-stage pipeline. Applying an average biotech P/E of 19x 2009E EPS (i...
|
|
|
|
|
